BlossomHill Therapeutics, Inc. (BLSM) – What Are Researchers Thinking About This Stock?

Shares of BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $35.00.

BLSM has been the subject of several analyst reports. HC Wainwright restated a “buy” rating on shares of BlossomHill Therapeutics in a report on Wednesday, September 30th. Guggenheim raised their price target on BlossomHill Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. JPMorgan Chase & Co. started coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 target price for the company. Weiss Ratings started coverage on BlossomHill Therapeutics in a research note on Tuesday, November 3rd. They issued a “sell (e-)” rating on the stock. Finally, Lifesci Capital assumed coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 price objective on the stock.

BlossomHill Therapeutics Trading Down 5.5%

Shares of BLSM stock traded down $0.82 during mid-day trading on Friday, reaching $14.02. 222,586 shares of the company’s stock traded hands, compared to its average volume of 169,753. BlossomHill Therapeutics has a 12 month low of $11.02 and a 12 month high of $27.99. The firm’s 50-day simple moving average is $18.01. The firm has a market cap of $445.56 million and a P/E ratio of -1.60.

BlossomHill Therapeutics (NASDAQ:BLSM) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.36). On average, sell-side analysts expect that BlossomHill Therapeutics will post -5.54 EPS for the current year.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.